Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients

被引:177
作者
Keidar, S [1 ]
Gamliel-Lazarovich, A
Kaplan, M
Pavlotzky, E
Hamoud, S
Hayek, T
Karry, R
Abassi, Z
机构
[1] Rambam Med Ctr, Dept Internal Med A, Lipid Res Lab, IL-31096 Haifa, Israel
[2] Rambam Med Ctr, Dept Vasc Surg & Transplantat, Haifa, Israel
[3] Technion Israel Inst Technol, Fac Med, IL-32000 Haifa, Israel
关键词
heart failure; mineralocorticoid receptor blockade; ACE2;
D O I
10.1161/01.RES.0000187500.24964.7A
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF), and spironolactone improves cardiovascular function and survival rates in patients with CHF. We hypothesized that the mineralocorticoid receptor blockade (MRB) exerted its beneficial effects by reducing oxidative stress and changing the balance between the counter-acting enzymes angiotensin-converting enzyme (ACE) and ACE2. Monocyte-derived macrophages were obtained from 10 patients with CHF before and after 1 month of treatment with spironolactone (25 mg/d). Spironolactone therapy significantly (P < 0.005) reduced oxidative stress, as expressed by reduced lipid peroxide content, superoxide ion release, and low-density lipoprotein oxidation by 28%, 53%, and 70%, respectively. Although spironolactone significantly (P < 0.01) reduced macrophage ACE activity by 47% and mRNA expression by 53%, ACE2 activity and mRNA expression increased by 300% and 654%, respectively. In mice treated for 2 weeks with eplerenone (200 mg (.) kg(-1) . d(-1)), cardiac ACE2 activity significantly (P < 0.05) increased by 2-fold and was paralleled by increased ACE2 activity in macrophages. The mechanism of aldosterone antagonist action was studied in mouse peritoneal macrophages (MPMs) in vitro. Although ACE activity and mRNA were significantly increased by 250 nmol/L aldosterone, ACE2 was significantly reduced. Cotreatment with eplerenone (2 mu mol/L) attenuated these effects. In MPM obtained from p47 knockout mice, where NADPH oxidase is inactive, as well as in control MPMs treated with NADPH oxidase inhibitor, aldosterone did not increase ACE or decrease ACE2. MRB reduced oxidative stress, decreased ACE activity, and increased ACE2 activity, suggesting a protective role for MRB by possibly increasing generation of angiotensin (1-7) and decreasing formation of angiotensin II. These effects are mediated, at least in part, by NADPH oxidase.
引用
收藏
页码:946 / 953
页数:8
相关论文
共 32 条
[1]  
Aviram M, 2001, METHOD ENZYMOL, V335, P244
[2]   Angiotensin-converting enzyme 2 is an essential regulator of heart function [J].
Crackower, MA ;
Sarao, R ;
Oudit, GY ;
Yagil, C ;
Kozieradzki, I ;
Scanga, SE ;
Oliveira-dos-Santos, AJ ;
da Costa, J ;
Zhang, LY ;
Pei, Y ;
Scholey, J ;
Ferrario, CM ;
Manoukian, AS ;
Chappell, MC ;
Backx, PH ;
Yagil, Y ;
Penninger, JM .
NATURE, 2002, 417 (6891) :822-828
[3]   A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[4]   Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure [J].
Farquharson, CAJ ;
Struthers, AD .
CIRCULATION, 2000, 101 (06) :594-597
[5]   Counterregulatory actions of angiotensin-(1-7) [J].
Ferrario, CM ;
Chappell, MC ;
Tallant, EA ;
Brosnihan, KB ;
Diz, DI .
HYPERTENSION, 1997, 30 (03) :535-541
[6]   Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes [J].
Harada, E ;
Yoshimura, M ;
Yasue, H ;
Nakagawa, O ;
Nakagawa, M ;
Harada, M ;
Mizuno, Y ;
Nakayama, M ;
Shimasaki, Y ;
Ito, T ;
Nakamura, S ;
Kuwahara, K ;
Saito, Y ;
Nakao, K ;
Ogawa, H .
CIRCULATION, 2001, 104 (02) :137-139
[7]   Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme [J].
Harmer, D ;
Gilbert, M ;
Borman, R ;
Clark, KL .
FEBS LETTERS, 2002, 532 (1-2) :107-110
[8]   Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice [J].
Hayek, T ;
Attias, J ;
Smith, J ;
Breslow, JL ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (04) :540-544
[9]   Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis - Studies in ACE-knockout mice type 2 [J].
Hayek, T ;
Pavlotzky, E ;
Hamoud, S ;
Coleman, R ;
Keidar, S ;
Aviram, M ;
Kaplan, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (11) :2090-2096
[10]   Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice [J].
Hayek, T ;
Hamoud, S ;
Keidar, S ;
Pavlotzky, E ;
Coleman, R ;
Aviram, M ;
Kaplan, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 43 (01) :140-147